This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Do 'Bionic Woman' Stocks Have the Right Parts?

Editor's note: This column was submitted by Stockpickr member Susanne Owen, also known as the Trading Nymph.

NBC's reconstructed Bionic Woman series is proving successful, but what about the companies whose technologies really could rebuild a Jaime Sommers into a bionic phenom?

It's been about a month since Jim Cramer featured his bionic picks on "Mad Money." So after recent earnings reports, buyouts news and DOJ settlements, the question arises: Have these proven good, constructive picks for building a powerful portfolio -- especially in light of the fact that the S&P 500 has fallen about 7.8% since then?

The Oct. 10 "Mad Money", starring the "always dashing" Jim Cramer, featured Stryker (SYK) and Smith & Nephew (SNN), two orthopedic products makers that build the replacement parts needed to fix faulty joints like hips and knees. Cramer also featured Alcon (ACL), which makes surgical equipment and devices as well as consumer eye-care products to treat eye diseases and disorders.

On his Oct. 12 "Mad Money" show, Cramer featured Tutogen Medical (TTG) as a speculative play. The company uses a process of tissue preservation to deliver sterile bio-implants that are used to repair various bone and other tissue defects in dental, spinal, urology, ophthalmology, head, neck and general surgery procedures. And finally, on his Oct. 16 show, Cramer featured Sonic Innovations (SNCI), which makes small, powerful hearing aids, as another speculative play.

A couple of these bionic plays have since had to fight the Department of Justice. On Sept. 27 Smith & Nephew signed an agreement with the DOJ to defer prosecution. At issue was whether Smith & Nephew (along with Zimmer (ZMH), Stryker (SYK), Biomet and Johnson & Johnson (JNJ) subsidiary DePuy Orthopaedics) gave kickbacks to doctors for choosing their products.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,287.95 +21.96 0.13%
S&P 500 2,013.04 +1.68 0.08%
NASDAQ 4,587.4470 -5.9780 -0.13%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs